Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

African-specific variability in the acetylcholine muscarinic receptor M4: association with cocaine and heroin addiction.

Levran O, Randesi M, Peles E, Correa da Rosa J, Ott J, Rotrosen J, Adelson M, Kreek MJ.

Pharmacogenomics. 2016 Jun;17(9):995-1003. doi: 10.2217/pgs-2016-0028. Epub 2016 Jun 7.

2.

The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders: A Potential Novel Treatment?

Jeon WJ, Dean B, Scarr E, Gibbons A.

Curr Neuropharmacol. 2015;13(6):739-49. Review.

3.

Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms.

Fisher HL, Murphy TM, Arseneault L, Caspi A, Moffitt TE, Viana J, Hannon E, Pidsley R, Burrage J, Dempster EL, Wong CC, Pariante CM, Mill J.

Epigenetics. 2015;10(11):1014-23. doi: 10.1080/15592294.2015.1099797.

4.

Changes in Muscarinic M2 Receptor Levels in the Cortex of Subjects with Bipolar Disorder and Major Depressive Disorder and in Rats after Treatment with Mood Stabilisers and Antidepressants.

Gibbons AS, Jeon WJ, Scarr E, Dean B.

Int J Neuropsychopharmacol. 2016 Apr 20;19(4). pii: pyv118. doi: 10.1093/ijnp/pyv118. Print 2016 Apr.

5.

Elevated Hippocampal Cholinergic Neurostimulating Peptide precursor protein (HCNP-pp) mRNA in the amygdala in major depression.

Bassi S, Seney ML, Argibay P, Sibille E.

J Psychiatr Res. 2015 Apr;63:105-16. doi: 10.1016/j.jpsychires.2015.02.006. Epub 2015 Feb 20.

6.

Understanding alcohol use disorders with neuroelectrophysiology.

Rangaswamy M, Porjesz B.

Handb Clin Neurol. 2014;125:383-414. doi: 10.1016/B978-0-444-62619-6.00023-9. Review.

7.

The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited.

van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA.

Eur J Pharmacol. 2015 Apr 15;753:114-26. doi: 10.1016/j.ejphar.2014.05.063. Epub 2014 Aug 5. Review.

8.

Event-Related Oscillations in Alcoholism Research: A Review.

Pandey AK, Kamarajan C, Rangaswamy M, Porjesz B.

J Addict Res Ther. 2012 Jan 12;Suppl 7(1). pii: 3844.

9.

Assessment of genetic and nongenetic interactions for the prediction of depressive symptomatology: an analysis of the Wisconsin Longitudinal Study using machine learning algorithms.

Roetker NS, Page CD, Yonker JA, Chang V, Roan CL, Herd P, Hauser TS, Hauser RM, Atwood CS.

Am J Public Health. 2013 Oct;103 Suppl 1:S136-44. doi: 10.2105/AJPH.2012.301141. Epub 2013 Aug 8.

10.
11.

Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Drevets WC, Zarate CA Jr, Furey ML.

Biol Psychiatry. 2013 Jun 15;73(12):1156-63. doi: 10.1016/j.biopsych.2012.09.031. Epub 2012 Nov 28. Review.

12.

The anterior cingulate cortex may enhance inhibition of lateral prefrontal cortex via m2 cholinergic receptors at dual synaptic sites.

Medalla M, Barbas H.

J Neurosci. 2012 Oct 31;32(44):15611-25. doi: 10.1523/JNEUROSCI.2339-12.2012.

13.

CHRM2, parental monitoring, and adolescent externalizing behavior: evidence for gene-environment interaction.

Dick DM, Meyers JL, Latendresse SJ, Creemers HE, Lansford JE, Pettit GS, Bates JE, Dodge KA, Budde J, Goate A, Buitelaar JK, Ormel J, Verhulst FC, Huizink AC.

Psychol Sci. 2011 Apr;22(4):481-9. doi: 10.1177/0956797611403318. Epub 2011 Mar 24.

14.

Expression profiling of a genetic animal model of depression reveals novel molecular pathways underlying depressive-like behaviours.

Blaveri E, Kelly F, Mallei A, Harris K, Taylor A, Reid J, Razzoli M, Carboni L, Piubelli C, Musazzi L, Racagni G, Mathé A, Popoli M, Domenici E, Bates S.

PLoS One. 2010 Sep 7;5(9):e12596. doi: 10.1371/journal.pone.0012596.

15.

Lack of association of a spontaneous mutation of the Chrm2 gene with behavioral and physiologic phenotypic differences in inbred mice.

Ding M, Arnold J, Turner J, Ramkumar V, Hughes LF, Trammell RA, Toth LA.

Comp Med. 2010 Aug;60(4):272-81.

16.

Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Furey ML, Khanna A, Hoffman EM, Drevets WC.

Neuropsychopharmacology. 2010 Nov;35(12):2479-88. doi: 10.1038/npp.2010.131. Epub 2010 Aug 25.

17.

Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder.

Cannon DM, Klaver JK, Gandhi SK, Solorio G, Peck SA, Erickson K, Akula N, Savitz J, Eckelman WC, Furey ML, Sahakian BJ, McMahon FJ, Drevets WC.

Mol Psychiatry. 2011 Apr;16(4):407-18. doi: 10.1038/mp.2010.24. Epub 2010 Mar 30.

18.

Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial.

Drevets WC, Furey ML.

Biol Psychiatry. 2010 Mar 1;67(5):432-8. doi: 10.1016/j.biopsych.2009.11.021. Epub 2010 Jan 15.

19.

Synergistic effects of genetic variation in nicotinic and muscarinic receptors on visual attention but not working memory.

Greenwood PM, Lin MK, Sundararajan R, Fryxell KJ, Parasuraman R.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3633-8. doi: 10.1073/pnas.0807891106. Epub 2009 Feb 11.

20.

Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects.

Gibbons AS, Scarr E, McLean C, Sundram S, Dean B.

J Affect Disord. 2009 Aug;116(3):184-91. doi: 10.1016/j.jad.2008.11.015. Epub 2008 Dec 21.

Supplemental Content

Support Center